Fuchs’ Endothelial Dystrophy

Fuchs’ dystrophy is a hereditary condition that gradually destroys the cells your cornea needs to stay clear. Left untreated it leads to permanent vision loss, but caught early it can be managed — and when surgery is needed, DMEK offers excellent outcomes with low rejection risk and fast recovery. Diagnosis, medical management, and DMEK surgery by cornea specialist Dr. Bonnie Sklar.

Woman in her sixties reading in bright natural light — clear vision after treatment for Fuchs' endothelial dystrophy at Berg-Feinfield, Los Angeles
Clinical image showing corneal guttae and corneal edema caused by Fuchs' endothelial dystrophy Clinical image. Individual presentation varies.

What Is Fuchs’ Dystrophy?

The cornea — the clear front surface of your eye — depends on a single layer of cells on its inner surface to stay transparent. These corneal endothelial cells act as pumps that continuously remove excess fluid. When they work properly the cornea stays clear; when they don't, it swells with fluid and clouds your vision.

In Fuchs’ endothelial dystrophy, a hereditary condition, these cells gradually deteriorate and die. As the cell count drops, the cornea loses its ability to regulate fluid and begins to swell — a process called corneal edema — producing increasingly blurry, foggy vision that worsens over time. It affects roughly 4% of people over 40, is more common in women, and often isn't noticed until vision changes appear in a person's 50s or 60s. A telling early sign is morning blur that clears as the day goes on, because the closed eye can't evaporate excess fluid overnight.

See the Stages

Signs of Fuchs’ Dystrophy

Symptoms usually begin gradually and worsen over years. Early disease may cause only mild disturbances; advanced disease significantly impairs vision.

Morning Blur That Clears

Blurry or foggy vision on waking that improves later in the day — one of the earliest and most telling signs.

Glare & Halos

Glare and halos around lights, particularly at night or in bright conditions, with difficulty driving at night due to reduced contrast.

Light Sensitivity

Increased sensitivity to light (photophobia) as the disease progresses.

Cloudy, Washed-Out Vision

Vision that looks cloudy or washed out regardless of your glasses prescription.

Vision Glasses Can't Fix

Fluctuating vision that your optometrist cannot fully correct with a new prescription.

Advanced-Stage Discomfort

In advanced disease, persistent blur throughout the day and eye pain from surface blistering (bullous keratopathy).

If Fuchs’ runs in your family: regular corneal evaluations are recommended even before symptoms appear. Early detection significantly expands your treatment options and timeline.

The Three Stages of Fuchs’ Dystrophy

Fuchs’ progresses through distinct stages over years or decades. Understanding your current stage is essential to determining the right treatment approach — and the right timing.

Stage 1 · Manage & Monitor

Early — Guttae Without Edema

Tiny deposits called guttae appear on the corneal endothelium and cell density begins to decline. Vision may be normal or only mildly affected, and most patients are unaware they have Fuchs’. Management focuses on monitoring, with hypertonic saline drops to ease morning blur.

Stage 2 · Monitor for Surgery

Intermediate — Stromal & Epithelial Edema

The cornea begins retaining fluid in the stroma. Vision becomes noticeably blurry, especially in the morning, and glare and halos worsen. Corneal thickness increases measurably on pachymetry. Hypertonic drops and the hair-dryer technique provide temporary relief, and surgical planning often begins here.

Stage 3 · Surgery Indicated

Advanced — Bullous Keratopathy

Fluid breaks through to the outer surface, forming painful blisters called bullae. Vision is severely impaired throughout the day and scarring may begin to develop. A corneal transplant — specifically DMEK — is typically required to restore vision and relieve pain.

Managing & Treating Fuchs’ Dystrophy

Treatment depends entirely on the stage of the disease. Early Fuchs’ is managed medically; advanced disease is treated surgically — and today's options are dramatically better than a decade ago.

Hypertonic Saline Drops

Early to moderate disease. Sodium chloride drops (5% NaCl) draw excess fluid out of the swollen cornea by osmosis. They don't stop the disease but can significantly reduce morning blur and improve daily comfort. Dr. Sklar recommends the appropriate formulation and frequency for your severity.

Hair-Dryer Technique

Practical management. Holding a hair dryer at arm's length and directing warm (not hot) air toward your face on waking helps evaporate surface moisture, easing morning blur. This is a genuine clinical recommendation, and combined with hypertonic drops it makes early Fuchs’ much more manageable.

DMEK

Advanced disease — first-line surgery. Descemet Membrane Endothelial Keratoplasty replaces only the diseased Descemet membrane and endothelial cells with a thin donor graft, typically giving excellent visual outcomes, fast recovery, and the lowest rejection rate of any corneal transplant. Learn about DMEK.

DSEK / DSAEK

Alternative surgical option. When DMEK isn't the best fit, DSEK replaces the inner corneal layers with a slightly thicker donor graft. It remains an excellent option with far faster recovery than full-thickness transplantation. Compare transplant types.

Lowest

Rejection risk of any corneal transplant

Weeks

Typical onset of visual improvement

~3mm

Incision size — no large corneal wound

No

Corneal graft sutures required

Why DMEK is preferred for Fuchs’: because only the diseased inner layer is replaced — not the entire cornea — DMEK is today's standard of care, with recovery, rejection risk, and visual outcomes that are significantly better than older full-thickness PKP transplantation.

What to Expect at Your Evaluation

Diagnosing Fuchs’ and staging it accurately requires more than a standard eye exam. Dr. Sklar combines advanced imaging and clinical tests to build a complete picture of your corneal health.

Slit Lamp Examination

The primary tool for detecting guttae, the tiny corneal deposits that are the hallmark of Fuchs’. A trained cornea specialist can detect early guttae before any symptoms occur.

Specular Microscopy

Photographs and counts the corneal endothelial cells for a precise density measurement. Declining cell counts are a key marker of progression and help guide the timing of surgery.

Corneal Pachymetry

Measures corneal thickness at multiple points. A cornea swelling with fluid is measurably thicker than normal, and pachymetry quantifies this and tracks change over time.

Topography & Tomography

3D mapping of the corneal surface and internal structure, used to detect irregular astigmatism from swelling and to guide surgical planning for DMEK.

Dr. Bonnie Sklar — Fuchs’ & Corneal Transplant Specialist

Dr. Sklar is Berg-Feinfield's fellowship-trained cornea specialist, with particular expertise in the surgical management of Fuchs’ endothelial dystrophy.

  • Cornea Fellowship, Duke

    Completed her cornea fellowship at Duke University Eye Center, one of the nation's most respected programs, and her residency at Wills Eye Hospital in Philadelphia.

  • Full Spectrum of Transplants

    Her practice centers on the full range of corneal transplantation — DMEK, DSEK, and PKP — along with keratoconus, cross-linking, and ocular surface disease.

  • DMEK Expertise

    For patients considering DMEK, her fellowship training provides the specialized background this technically demanding procedure requires.

  • Early Staging & Baselines

    You don't need to be symptomatic to benefit — early staging establishes a baseline and allows for properly timed intervention if the disease progresses.

Dr. Bonnie Sklar, MD — fellowship-trained cornea specialist at Berg-Feinfield, Los Angeles

Fuchs’ Dystrophy Care Near You

Dr. Sklar sees Fuchs’ dystrophy patients across Berg-Feinfield's Los Angeles-area offices, with corneal evaluations and DMEK surgical consultations available throughout the region.

Sherman Oaks

13320 Riverside Drive
Suite 114
Sherman Oaks, CA 91423
(818) 501-3937

Office details →

Beverly Hills

462 N. Linden Drive
Suite 441
Beverly Hills, CA 90212
(866) 273-3327

Office details →

Fuchs’ Dystrophy — Your Questions Answered

Yes. Fuchs’ dystrophy has a strong hereditary component and tends to run in families, associated with mutations in genes affecting corneal endothelial cell function. If a parent has Fuchs’, their children have roughly a 50% chance of inheriting it. Regular eye exams, including slit lamp evaluation of the cornea, are recommended for first-degree relatives of anyone diagnosed.
No. Many people have early-stage disease that stays manageable with hypertonic saline drops and routine monitoring for years or even decades. Surgery becomes appropriate when vision loss significantly affects daily function, when drops no longer provide adequate relief, or when painful surface blistering develops. The decision to proceed with DMEK is individualized, depending on disease stage, visual demands, and overall health.
Yes, but it requires careful planning. Cataract surgery stresses corneal endothelial cells, and the reduced cell reserve in Fuchs’ means the cornea may decompensate after an otherwise routine procedure. In moderate to severe cases, combining cataract surgery with DMEK in a single triple procedure or staging them sequentially is often preferred. A thorough corneal evaluation, including specular microscopy and pachymetry, before any intraocular surgery is essential, and Dr. Sklar evaluates each case individually.
DMEK is an outpatient procedure that typically takes one to two hours. Afterward, patients maintain face-down positioning for 24 hours so the thin donor graft can attach properly. Most notice meaningful visual improvement within weeks, with vision continuing to refine over several months, and long-term anti-rejection steroid drops are required. Compared with older full-thickness PKP, DMEK offers dramatically faster recovery, lower rejection risk, and better visual outcomes for most Fuchs’ patients.
DMEK is covered by most medical insurance plans, including Medicare, when it is medically necessary — which it typically is for advanced Fuchs’ causing significant vision impairment. Coverage includes the surgeon's fee, facility fee, anesthesia, and donor tissue, and prior authorization is generally required. Our team verifies your benefits and manages the authorization process before scheduling.
This is a good position to be in — early detection gives you the most options. If guttae have been identified but you have no significant symptoms, a baseline evaluation with a cornea specialist is the right next step. Dr. Sklar performs specular microscopy to quantify your endothelial cell count, pachymetry to measure corneal thickness, and imaging to document the extent of guttae. This baseline is invaluable for tracking progression, and many patients with early Fuchs’ need nothing more than annual monitoring for years.

Clearer Vision Starts With the Right Specialist

Whether you've just been told you have guttae or you've been living with Fuchs’ dystrophy for years, Dr. Sklar and the Berg-Feinfield cornea team will give you an honest assessment of where you are and what your options are.